Monopar Therapeutics is an emerging biopharmaceutical company focused on developing innovative drug combinations to improve clinical outcomes in advanced cancer. Monopar currently has two compounds in development: Validive® (clonidine mucobuccal tablet; clonidine MBT), a mucoadhesive local anti-inflammatory tablet for the prevention and treatment of severe oral mucositis (SOM) in head and neck cancer patients; and MNPR-101 (formerly huATN-658), a humanized monoclonal antibody, which targets the urokinase plasminogen activator receptor (uPAR), for the treatment of advanced solid cancers. MNPR-101 (huATN-658) is being developed in collaboration with Cancer Research UK. Monopar’s team is located in San Francisco, CA and Chicago, IL.
Licensing, developing and commercializing transformative Oncology therapeutics
Multiple factors drive our passion for Oncology
The numbers behind our research define its opportunities
Validive is a Phase 3 asset to prevent severe oral mucositis in patients undergoing radiation treatment for head and neck cancer. MNPR-101 (huATN-658) is a humanized monoclonal antibody targeting urokinase plasminogen activator receptor (uPAR) positive solid tumors with development funded through Phase 1b via a partnership with Cancer Research UK.